Leidos Just Beat Again. The Stock Is Down 29%. Here's the Opportunity No One Is Talking About.

Do you know what creates the best risk/reward setup in dividend investing? A mission-critical company that just proved its earnings power, sitting at roughly a 40% discount to its own high, with a valuation that would look cheap on any other day - but nobody is looking because the political headlines make them nervous.

That is Leidos today.

The defense and government IT contractor reported second-quarter results this morning. Revenue came in at $4.56 billion, up 7.2% year-over-year and beating the $4.44 billion consensus. Adjusted earnings per share of $3.26 cleared Wall Street's $2.91 estimate by 12%. Free cash flow margin jumped to 16.7%, up from 10.7% a year ago. The company slightly raised its full-year revenue midpoint to $18.3 billion and its adjusted EPS midpoint to $12.35. Backlog stands at $48.7 billion, up 5.4% year-over-year.

And yet the stock is down 28.5% year-to-date. It's sitting at roughly $129, about 40% below its 52-week high of $206. The stock jumped 8.5% this morning on the earnings beat, but that's not enough to offset a brutal year.

I don't think this setup is about weak fundamentals. I think it's about fear - the kind of fear that creates the exact entry point the equity yield curve approach is built to exploit.

What's Driving the Fear

Leidos has been caught in the crossfire of political uncertainty. Throughout 2025 and into 2026, the Department of Government Efficiency - the Musk-led initiative to slash federal spending - cast a shadow over government contractors. Leidos, as one of the largest federal IT and defense services providers, was a natural target for investor anxiety. The stock was down 37% year-to-date by mid-June.

In June, Jefferies downgraded Leidos to Hold from Buy, cutting its price target from $185 to $140, citing uncertainty around defense spending and margin sustainability. Around the same time, news surfaced that the Defense Health Agency planned to move away from Leidos as the lead systems integrator for its electronic health record system - a contract Leidos had held since 2015. That single event triggered outsized selling.

But here's what matters more than what was being feared: the fear catalyst has evaporated. DOGE officially shut down on July 4th. The Pentagon's FY2027 budget, as advanced by the House Appropriations Committee in June, sits at $1.07 trillion - the largest military budget in U.S. history, a $234 billion increase over FY2026. Defense Secretary Hegseth's internal orders to draft 8% annual cuts are being drowned out by a spending bill that does the opposite.

The fear that was pricing this stock is no longer the reality the company is operating in.

Pricing Power Is The Real Story

The question that matters for dividend investors isn't whether the headlines were scary. It's whether Leidos can raise prices without losing customers. The answer is structurally yes.

Leidos sits at the intersection of national security IT, military intelligence systems, cybersecurity infrastructure, and critical government operations. These are not discretionary purchases. When the Office of Naval Intelligence awards a contract to modernize its intelligence systems, or when the Army signs an $869 million deal for AI-enabled decision-making systems, or when Sierra Space selects Leidos to provide infrared sensing payloads for the Golden Dome missile tracking initiative - these are mission-critical relationships. The government doesn't swap out its core technology integrators on a quarterly cycle.

That is the definition of pricing power. The customer doesn't have a viable alternative, and the switching costs are enormous.

Q2 proved the mechanism. Revenue grew 7.2% year-over-year. Adjusted EBITDA came in at $631 million with a 13.8% margin - beating estimates. The operating margin contraction to 11.3% from 13.4% year-over-year deserves attention, and I'll address it below, but the core point stands: the revenue engine is accelerating, not stuttering.

The Valuation Discount

Leidos trades at 11.5 times trailing earnings and 10.7 times forward earnings. EV/EBITDA is 9.4x. Price-to-sales is 0.93x.

Compare that to its defense peers: Lockheed Martin at 21.5x trailing PE, Northrop Grumman at 17.4x, RTX at 37.6x, and Huntington Ingalls at 19.2x. Leidos trades at roughly half the earnings multiple of the largest defense primes, even though its revenue growth of 7.2% is in line with or ahead of many of these same companies.

That gap exists because the market is pricing in two concerns: the DHA health record contract risk and the company's elevated balance sheet. Both are real. Neither is fatal.

The Balance Sheet Problem

This is where the story gets complicated, and where I need to be honest. Leidos carries $10.3 billion in total debt against $5.1 billion in equity - a debt-to-equity ratio of 125%. Net debt is $5.9 billion. That is not light.

The debt load came primarily from the Entrust Solutions Group acquisition that closed in Q1 2026, funded with $1.4 billion in senior notes and $300 million in commercial paper. The Entrust deal fits Leidos' NorthStar 2030 strategy, expanding its cybersecurity and digital infrastructure capabilities. But it means the balance sheet is stretched.

What offsets this: free cash flow of $1.86 billion over the trailing twelve months, up 52% year-over-year. Operating cash flow is $2.0 billion. The company generates enough cash to service its debt and has strong coverage ratios. The current ratio is 140%, and the quick ratio is 129%.

From a dividend safety standpoint, the payout ratio is only 15% of trailing earnings. Leidos has raised its dividend for six consecutive years and paid for twelve years total. The current yield is 1.3%. That's not a yield play - it's a dividend growth play, and the low payout ratio gives the company enormous room to accelerate increases as earnings recover.

I wouldn't call this balance sheet pristine. But I would say it's manageable for a company generating nearly $2 billion in operating cash flow, and the dividend is well protected.

The Operating Margin Dip - Signal or Noise?

Leidos' operating margin fell to 11.3% in Q2 from 13.4% a year ago. That's a real hit. Expenses grew faster than revenue.

The context matters. The Q1 entrust acquisition integration costs $39 million. The company is also building out new AI and digital infrastructure capabilities under its NorthStar strategy, which means near-term spending before the revenue tailwind arrives. CEO Tom Bell called the second half of 2026 "the launchpad for multiyear growth acceleration." Whether that materializes is the key variable.

The free cash flow margin, however, improved sharply to 16.7% from 10.7%. Operating cash flow is strong. The operating margin compression doesn't tell the whole story.

The Macro Regime Fits

I believe inflation is likely to remain more persistent than the market wants to admit. The July ISM Manufacturing PMI registered 55.6, the highest reading since May 2022, with the new orders index at 56.7 and the prices index still in expansion territory at 71.1. Manufacturing employment returned to growth after 33 months of contraction.

In a regime where inflation stays above traditional targets and government spending on defense and infrastructure is the largest in history, companies that provide mission-critical services with pricing power are the ones that compound. Leidos fits that profile. The government isn't going to stop buying cybersecurity, intelligence systems, AI-enabled military decision tools, or air traffic management because inflation is sticky.

The Equity Yield Curve Entry

The equity yield curve is about finding businesses in the sweet spot - moderate yields with strong dividend growth potential - and buying them when cyclical or political downturns temporarily inflate the yield. Leidos is at that inflection point.

A 1.3% current yield with a 15% payout ratio and six years of consecutive dividend increases is a compounding setup waiting for patience. If adjusted EPS delivers around $12.35 this year and the payout ratio stays at current levels, the dividend can grow meaningfully without stress. If margins recover toward their historical range, the growth accelerates further. The math on a 20- to 30-year horizon is straightforward: even a modest starting yield with 10% annual dividend growth creates a yield on cost that traditional income vehicles can't match.

This is the equity yield curve in action. The stock is out of favor. The business is executing. The valuation is compressed. The fear catalyst (DOGE, spending uncertainty) has resolved or is resolving.

The Risk I'm Not Ignoring

The DHA health record contract departure is real revenue loss that needs to be replaced. Leidos needs to win the follow-on work or offset it elsewhere. The backlog of $48.7 billion suggests they have plenty of work in the pipeline, but the composition of that backlog matters more than the headline number.

The debt level from the Entrust acquisition needs time to normalize. If revenue growth stalls or margins compress further, leverage becomes a concern. I'm watching the Q3 and Q4 results to see if the "launchpad" language from management materializes into margin recovery.

The $1.07 trillion defense budget is a record, but it's also politically fragile. Future administrations or Congress could reverse course. The 8% cut proposals from within the Pentagon, while currently drowned out by the spending bill, represent a real structural risk over a multi-year horizon.

The Verdict

Leidos is not a yield-chase play. It belongs in the income-growth sleeve - the part of the portfolio where you accept a modest current yield in exchange for a business that can compound its payout through pricing power, mission-critical positioning, and low payout ratio flexibility.

From an income and risk/reward point of view, the stock sitting at 10.7x forward earnings with accelerating revenue, growing backlog, a 15% payout ratio, and $48.7 billion in contracted future work is the kind of setup that rewards patience and punishes panic. The fear was real. The fundamentals tell a different story.

This is not a stock I'd treat as a quick trade. It's a position for investors who understand that defense IT and intelligence services are TOLL stocks - companies the economy and the government literally cannot function without - and who are willing to sit through the noise while the compounding does the work.